Advertisement
Canada markets close in 1 hour 42 minutes
  • S&P/TSX

    21,979.61
    +94.23 (+0.43%)
     
  • S&P 500

    5,106.60
    +58.18 (+1.15%)
     
  • DOW

    38,287.18
    +201.38 (+0.53%)
     
  • CAD/USD

    0.7319
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    83.90
    +0.33 (+0.39%)
     
  • Bitcoin CAD

    87,457.98
    -927.31 (-1.05%)
     
  • CMC Crypto 200

    1,332.18
    -64.36 (-4.61%)
     
  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     
  • RUSSELL 2000

    2,003.85
    +22.73 (+1.15%)
     
  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     
  • NASDAQ

    15,934.56
    +322.80 (+2.07%)
     
  • VOLATILITY

    15.09
    -0.28 (-1.82%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Valeant Pharmaceuticals before Its Q2 2018 Earnings

Valeant Pharmaceuticals before Its Q2 2018 Earnings

Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.